In a phase Ib clinical trial combining durvalumab with trastuzumab in heavily pretreated HER2+/PD-L1– metastatic BC, no responses were seen and evidence of cytotoxic T-cell exhaustion was found (Chia et al., 2019). This evidence concerns the gene ERBB2 and breast cancer.